Novo Nordisk's generative AI deployment to 20,000 employees has useful insights for companies working to scale their own AI efforts. Its leaders navigated three key challenges: a midcycle enthusiasm dip that can kill GenAI adoption, function-specific needs that demand tailored training, and cultural resistance. Novo Nordisk's solution combined champion networks, targeted enablement, and adaptive governance ' with senior employees serving as unexpected change agents. As companies move from experimentation to enterprisewide adoption, many struggle not with the tools themselves but with the organizational transformation required to integrate them meaningfully into people's daily work. Tools will keep evolving: It is the human side of the equation that determines whether GenAI initiatives truly succeed. We studied one of the largest real-world generative AI deployments to date ' at multinational pharmaceutical company Novo Nordisk. Its experience shows that success hinges not just on...
learn more
Ratings & Reviews
Entrepreneur & Investor
YOU MIGHT ALSO LIKE